Barclays raised the price target for the Abbott Laboratories (NYSE:ABT) stock to “an Overweight”. The rating was released on May 25, 2021. The research report from BTIG Research has upgraded the stock from Neutral to Buy, with a price target set at $140. The stock was initiated by Wolfe Research, who disclosed in a research note on September 11, 2020, to Outperform and set the price objective to $124. In their research brief published June 01, 2020, Goldman analysts downgraded the Abbott Laboratories stock from Neutral to Sell with a price target of $84.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Abbott Laboratories (NYSE:ABT) raised 0.40% to close Friday’s market session at $119.74, higher as compared to yesterday’s close. The stock price fluctuated between $119.24 and $120.24 throughout the trading session with the volume trading being 4285682 shares, which represented a significant variation when compared to the three months average volume of 6.38 million shares. The firm’s stock price fluctuated 2.20% within the last five trades and 9.80% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 7.58% in the last 6 months and -0.96% was subtracted to its value over the previous 3 months. ABT stock is trading at a margin of 5.38%, 4.20% and 4.80% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ABT deals in the Healthcare domain. The stock is trading -6.85 percent below its 52-week high and 30.56 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 18.21. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Abbott Laboratories’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 18.10 percent and the profit margin is 15.30 percent, and the company has reported a gross margin of 56.90 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $211.90 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Abbott Laboratories (NYSE:ABT) is 37.29. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 25.83. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 5.68 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.34, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.70 percent of Abbott Laboratories shares are owned by insiders, and 75.70 percent are held by financial institutions. Watkin Jared, the SENIOR VICE PRESIDENT at Abbott Laboratories (ABT) has sold 94,576 shares of firm on Apr 30 at a price of $119.90 against the total amount of $11.34 million. In another inside trade, BIRD ROGER, SENIOR VICE PRESIDENT of Abbott Laboratories (NYSE:ABT) sold 9,439 shares of the firm on Apr 27 for a total worth of $1.15 million at a price of $122.00. An inside trade which took place on Apr 27, SENIOR VICE PRESIDENT of Abbott Laboratories Karam Sammy sold 8,600 shares of firm against total price of $1.05 million at the cost of $122.00 per share.